The FDA Hormone Therapy Label Change (2026)

What happened on February 12, 2026

On February 12, 2026, the U.S. Food and Drug Administration approved labeling changes to the first six menopausal hormone therapy products. Those changes removed boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia that had appeared on HRT labels since 2003.

The six products span all four HRT categories — estrogen-only systemic, combined estrogen-plus-progestogen systemic, progestogen-only, and vaginal estrogen. The FDA's action followed a scientific literature review that began in November 2025, when HHS and the FDA asked 29 drug companies to submit proposed labeling changes across menopausal hormone therapy products. More products are expected to follow as those submissions are reviewed.

The change updates regulatory labeling to better reflect the evidence that has accumulated since the original 2002 Women's Health Initiative study, which those warnings had been based on. The WHI studied older women — average age 63 — on older synthetic hormones, and its findings were applied to a much broader population for over two decades. Menopause societies in the U.S. and internationally have held a different risk position for years; the FDA's 2026 action brings the label closer to that clinical consensus.

What did not change

The FDA kept the boxed warning about endometrial cancer for systemic estrogen-alone products. This warning applies to women with a uterus who take systemic estrogen without a progestogen. The risk of uterine cancer from unopposed systemic estrogen is well-characterised and clinically significant. Women with a uterus who are prescribed systemic estrogen should always be prescribed a progestogen alongside it. This has not changed and is not under review.

Vaginal estrogen for local symptoms — dryness, discomfort, and genitourinary symptoms — was already considered very low-risk before this update, due to its minimal systemic absorption. The 2026 change does not alter that picture; it was already the safest end of the HRT spectrum.

What this is not

The February 2026 label update does not mean hormone therapy is now safe for everyone. Risks remain individual. Your personal and family history — including cardiovascular history, prior blood clots, breast cancer history, and other factors — still shapes whether HRT is appropriate for you and, if so, in what form and at what dose. A clinician who has reviewed your full medical history should still walk through the risk conversation that applies to you specifically.

This update changes the risk conversation, not the conclusion. A good clinician will now be able to say: "The labeling has caught up with the evidence, here is what the updated picture means for your situation." That conversation should still be individual, not a blanket reassurance.

The evidence behind the change

Two findings are particularly relevant for women deciding whether to start HRT and when. Evidence from observational studies and re-analyses supports a reduced all-cause mortality risk and a reduced fracture risk when hormone therapy is initiated within approximately 10 years of menopause onset — often before age 60. This is sometimes called the "timing hypothesis" or "window of opportunity." It does not apply equally to women who start hormone therapy many years after menopause, particularly those who have had extended periods without estrogen.

The Menopause Society (formerly NAMS) and the British Menopause Society have both published position statements reflecting this evidence. The FDA's 2026 label update is consistent with this view, even though the FDA's mandate is labeling accuracy rather than clinical guidance.

What it means before your first consult

The practical implication is that the conversation you should expect from a menopause-trained clinician has become clearer. A good online HRT provider will now discuss your risk in terms of your age, how long it has been since your last period, your medication form (oral pills carry a higher clot risk than transdermal patches or gels), and your personal history — not in terms of a blanket 2003-era warning.

If you have a uterus, any responsible prescriber will still address progesterone. If your history includes factors that change the risk-benefit picture — prior cardiovascular events, a clotting disorder, estrogen-receptor-positive breast cancer — the label change does not erase those considerations. Some situations belong in a specialist's office rather than an online intake form, and a good provider will tell you that during screening.

• If you are under 60 and within 10 years of menopause onset, the updated evidence base and the 2026 label change are most relevant to your situation. The benefit-risk picture in this group is generally considered more favorable than it was understood to be in 2002.
• If you are over 60 or more than 10 years past menopause, the picture is more nuanced, and a clinician-led review matters more, not less.
• If you have a complex history,the label change does not simplify your situation. It changes the conversation your clinician should be having with you — it doesn't make the conversation unnecessary.

The best starting point before a consult is to understand your own symptom profile, your uterus status, your insurance and state availability, and the basic FDA-approved vs compounded distinction. The HRT Index Path Framework can help you map that before your first appointment.

Sources

• U.S. Food and Drug Administration — approved labeling changes to menopausal hormone therapy products, February 12, 2026.
• HHS / FDA — November 2025 scientific literature review and request to 29 drug companies.
• The Menopause Society (formerly NAMS) — hormone therapy position statement and clinical guidelines.
• Women's Health Initiative — original 2002 study and subsequent re-analyses.